TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Instagram Outage Disrupts Thousands of U.S. Users 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
MELBOURNE, Australia, July 31, 2017 -- Telix Pharmaceuticals Limited (“Telix”) is pleased to announce the completion of a Master Services Agreement (“MSA”) with Cyclotek (Aust) Pty Ltd (“Cyclotek”). Under the agreement, Cyclotek will provide Telix with radiopharmaceutical manufacturing and distribution services for Telix’s pipeline of oncology products, for both clinical trial purposes and, where appropriate, prescriber exemption use.
Telix is developing a pipeline of therapeutic and diagnostic radiopharmaceutical products for use in a variety of oncology settings. As an Australian biotechnology company, Telix is committed to ensuring that engagement with leading Australian cancer hospitals are an integral part of the company’s clinical development activity, paving the way for domestic patient access in the future.1
Telix CEO Christian Behrenbruch stated, “We are very pleased to be working with Cyclotek to manufacture our products for the ANZ region. We’ve chosen to work with the Cyclotek team because of their experience, stellar track-record of delivering product and effective integration with both domestic and international clinical studies.”
Cyclotek Managing Director Greg Santamaria commented, “It’s great to see the emergence of a new radiopharmaceutical company with a late-stage product development pipeline that is committed to including Australian clinical sites in its development activities. We look forward to partnering with Telix for both clinical trials and ultimately the delivery of product to patients.”
About Telix Pharmaceuticals Limited
Telix is a clinical-stage biopharmaceutical company headquartered in Melbourne, Australia. Telix is developing an advanced portfolio of clinical-stage products that address significant unmet medical needs in renal, prostate and brain (glioblastoma) cancer. Telix’s pipeline consists of “theranostic” radiopharmaceuticals, agents that can be used both diagnostically (via PET imaging) and therapeutically for patient benefit. Telix is an unlisted public company. For more information go to www.telixpharma.com.
About Cyclotek (Aust) Pty Ltd
Cyclotek has been the major supplier of Positron Emission Tomography (PET) radiopharmaceuticals since 2001. It currently operates four manufacturing facilities in Australia and New Zealand, and is rapidly expanding its facilities, and diversifying into manufacture of therapeutic radiopharmaceuticals. Cyclotek facilities are licenced by the Australian Therapeutic Goods Administration (TGA) to manufacture medicines according to the Code of Good Manufacturing Practice (GMP). For more information go to www.cyclotek.com.
1 Subject to applicable regulatory approvals or usage exemptions. Telix does not currently have regulatory authorization for the sale or use of any of its products in Australia or New Zealand.
Contact Telix Pharmaceuticals Limited Dr Christian Behrenbruch Tel.: +61 (0)406063247 Email: [email protected] Cyclotek (Aust) Pty Ltd Mr Greg Santamaria Tel.: +61 418 554 353 Email: [email protected]
